Market Cap | 187.12M | P/E | - | EPS this Y | -5.30% | Ern Qtrly Grth | - |
Income | -89.73M | Forward P/E | -2.55 | EPS next Y | 15.00% | 50D Avg Chg | -23.00% |
Sales | 398k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -56.00% |
Dividend | N/A | Price/Book | 2.71 | EPS next 5Y | - | 52W High Chg | -85.00% |
Recommedations | 2.60 | Quick Ratio | 3.31 | Shares Outstanding | 216.15M | 52W Low Chg | 13.00% |
Insider Own | 9.93% | ROA | -39.32% | Shares Float | 172.86M | Beta | 1.69 |
Inst Own | 56.28% | ROE | -84.01% | Shares Shorted/Prior | 35.28M/34.52M | Price | 0.87 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 2,309,898 | Target Price | 3.92 |
Oper. Margin | -22,103.52% | Earnings Date | May 4 | Volume | 2,127,546 | Change | -0.88% |
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.